
Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class AI-powered techbio platform. The platform integrates real-world patient data with advanced biology to create individualized patient tumor avatars that simulate drug responses, improving clinical trial success rates and patient recruitment. Orakl markets two AI-powered commercial products, O-Predict and O-Validate, which forecast patient responses and provide biological evidence for target validation, respectively. The company targets colorectal and pancreatic cancers, addressing major unmet medical needs, and aims to transform drug development by enabling better decision-making and strategic partnerships with pharmaceutical companies. Orakl has raised nearly €15 million in funding and is building a dedicated business team to support its growth and market entry.

Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class AI-powered techbio platform. The platform integrates real-world patient data with advanced biology to create individualized patient tumor avatars that simulate drug responses, improving clinical trial success rates and patient recruitment. Orakl markets two AI-powered commercial products, O-Predict and O-Validate, which forecast patient responses and provide biological evidence for target validation, respectively. The company targets colorectal and pancreatic cancers, addressing major unmet medical needs, and aims to transform drug development by enabling better decision-making and strategic partnerships with pharmaceutical companies. Orakl has raised nearly €15 million in funding and is building a dedicated business team to support its growth and market entry.
Founded: 2023 (spin‑out from Gustave Roussy)
Headquarters: Villejuif / Paris region, France
Focus: AI-powered precision oncology using patient-derived tumor avatars (organoids) and multimodal data
Products: O-Predict and O-Validate (AI commercial products)
Known funding: ≈ €14–15M across 2023–2024 (seed / pre-seed rounds)
| Company |
|---|
Preclinical and clinical de-risking for oncology drug discovery and development, with initial tumor-type focus on colorectal and pancreatic cancers.
2023
Biotechnology Research
€3,000,000
Reported pre-seed/seed round
€11,000,000
Seed round with participation from multiple investors
“Singular; Bpifrance; Speedinvest; Verve Ventures; HCVC; SistaFund; Amazon Web Services”
At Orakl Oncology , we are accelerating the development of oncology treatments. Today, fewer than 5% of new cancer drugs succeed in clinical trials. Clearly, new methods are needed. We combine cutting-edge biology and AI to build the next generation of insight platforms with the world’s largest cohort of patient tumor avatars. These avatars fuel our AI-powered predictive engine , helping to anticipate clinical trial outcomes, validate therapies, and uncover new drug candidates. By generating multimodal, real-world data, we deliver insights that consistently outperform existing solutions.
Our mission is simple yet ambitious: to who need them - and to make drug development smarter, faster, and more personalized. We collaborate with top hospitals, research institutes, and pharmaceutical companies worldwide. Backed by leading investors, we are a at the intersection of science and technology.
Orakl’s develops a rapidly scaling operational platform that cultures, expands, freezes, and screens hundreds of patient-derived organoids (PDOs). As a Platform Engineering Intern , you will work hand-in-hand with the Orakl Oncology CTO on problems that sit at the heart of the company’s execution: designing, modeling, and optimizing the systems that govern how organoids move through the organization.
You will take ownership of analyzing Orakl’s end-to-end organoid operations as a production system—identifying bottlenecks, defining performance metrics, and translating biological workflows into quantitative, optimizable processes . Your work will directly inform how capacity is planned, how resources are allocated, and how the platform scales reliably as demand increases.
You will address high-impact operational questions with real constraints: how to optimize duplication and expansion strategies under limited lab capacity; how to model the optimal number of organoid lines to thaw, expand, or freeze at any given time; how to integrate stochastic arrivals of fresh patient samples into deterministic planning; how to increase weekly screening throughput without sacrificing data quality; and how to maintain rigorous traceability while minimizing operational overhead. You will collaborate closely with wet-lab operators, operations planners, and data scientists, turning analysis into deployable process changes.
Your Missions
We are looking for a curious, dynamic, creative and rigorous intern to join us. There is no formal training for the job we’re offering : it’s new. We imagine that candidates will be scientists interested in industry, engineers curious about biology labs, business students with a passion for the life sciences, or anybody else interested in scaling lab operations.
Needs to Have
Nice-to-Haves
HR Call (15 minutes call) – An initial discussion to better understand your background, experiences, and motivations.
Technical Interview (45 minutes call) – A deep dive into your technical skills and expertise relevant to the role.
Founder Interview: As final step of our recruitment process, you will meet the founders of Orakl Oncology in person at our office. This meeting is an opportunity for the founders to assess cultural fit and ensure alignment with our company values.